Bedard, P. L., Hyman, D. M., Davids, M. S. & Siu, L. L. Small molecules, big impact: 20 years of targeted therapy in oncology. Lancet 395, 1078–1088 (2020).

CAS  PubMed  Google Scholar 

Flaherty, K. T., Le, D. T. & Lemery, S. Tissue-agnostic drug development. Am. Soc. Clin. Oncol. Educ. Book 37, 222–230 (2017).

PubMed  Google Scholar 

FDA. FDA Approves Entrectinib for NTRK Solid Tumors and ROS-1 NSCLC https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc (2019).

FDA. FDA Approves Larotrectinib for Solid Tumors with NTRK Gene Fusions https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions (2018).

FDA. FDA Approves Pembrolizumab for Adults and Children with TMB-H Solid Tumors https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors (2020).

FDA. FDA Grants Accelerated Approval to Pembrolizumab for First Tissue/site Agnostic Indication https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication (2017).

FDA. FDA Grants Accelerated Approval to Dostarlimab-gxly for dMMR Advanced Solid Tumors https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-advanced-solid-tumors (2022).

Rindi, G. et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod. Pathol. 31, 1770–1786 (2018).

PubMed  PubMed Central  Google Scholar 

Yao, J. C. et al. One hundred years after ‘carcinoid’: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 26, 3063–3072 (2008).

PubMed  Google Scholar 

Dasari, A. et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 3, 1335–1342 (2017).

PubMed  PubMed Central  Google Scholar 

Frilling, A. et al. Neuroendocrine tumor disease: an evolving landscape. Endocr. Relat. Cancer 19, R163–R185 (2012).

CAS  PubMed  Google Scholar 

Williams, E. D. & Sandler, M. The classification of carcinoid tumours. Lancet 1, 238–239 (1963).

CAS  PubMed  Google Scholar 

WHO Classification of Tumours Editorial Board. Digestive System Tumours: WHO Classification of Tumours, 5th Edition (International Agency for Research on Cancer, 2019).

WHO Classification of Tumours Editorial Board. Thoracic Tumours: WHO Classification of Tumours, 5th Edition (International Agency for Research on Cancer, 2021).

Stelwagen, J., de Vries, E. G. E. & Walenkamp, A. M. E. Current treatment strategies and future directions for extrapulmonary neuroendocrine carcinomas: a review. JAMA Oncol. 7, 759–770 (2021).

PubMed  Google Scholar 

Chang, M. T. et al. Small-cell carcinomas of the bladder and lung are characterized by a convergent but distinct pathogenesis. Clin. Cancer Res. 24, 1965–1973 (2018).

CAS  PubMed  Google Scholar 

Gluckman, C. R. & Metz, D. C. Gastric neuroendocrine tumors (Carcinoids). Curr. Gastroenterol. Rep. 21, 13 (2019).

PubMed  Google Scholar 

Perri, G., Prakash, L. R. & Katz, M. H. G. Pancreatic neuroendocrine tumors. Curr. Opin. Gastroenterol. 35, 468–477 (2019).

CAS  PubMed  Google Scholar 

Naraev, B. G. et al. Management of diarrhea in patients with carcinoid syndrome. Pancreas 48, 961–972 (2019).

CAS  PubMed  PubMed Central  Google Scholar 

Robelin, P. et al. Characterization, prognosis, and treatment of patients with metastatic lung carcinoid tumors. J. Thorac. Oncol. 14, 993–1002 (2019).

CAS  PubMed  Google Scholar 

Hermans, B. C. M. et al. Unique metastatic patterns in neuroendocrine neoplasms of different primary origin. Neuroendocrinology 111, 1111–1120 (2021).

CAS  PubMed  Google Scholar 

Riihimäki, M., Hemminki, A., Sundquist, K., Sundquist, J. & Hemminki, K. The epidemiology of metastases in neuroendocrine tumors. Int. J. Cancer 139, 2679–2686 (2016).

PubMed  Google Scholar 

Rekhtman, N. et al. Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices. Mod. Pathol. 32, 1106–1122 (2019).

CAS  PubMed  PubMed Central  Google Scholar 

Moertel, C. G., Weiland, L. H., Nagorney, D. M. & Dockerty, M. B. Carcinoid tumor of the appendix: treatment and prognosis. N. Engl. J. Med. 317, 1699–1701 (1987).

CAS  PubMed  Google Scholar 

Grozinsky-Glasberg, S. et al. Current size criteria for the management of neuroendocrine tumors of the appendix: are they valid? Clinical experience and review of the literature. Neuroendocrinology 98, 31–37 (2013).

CAS  PubMed  Google Scholar 

Raymond, E. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 501–513 (2011).

CAS  PubMed  Google Scholar 

Cives, M. & Strosberg, J. R. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J. Clin. 68, 471–487 (2018).

PubMed  Google Scholar 

Rudin, C. M., Brambilla, E., Faivre-Finn, C. & Sage, J. Small-cell lung cancer. Nat. Rev. Dis. Prim. 7, 3 (2021).

PubMed  Google Scholar 

Ko, J., Winslow, M. M. & Sage, J. Mechanisms of small cell lung cancer metastasis. EMBO Mol. Med. 13, e13122 (2021).

CAS  PubMed  Google Scholar 

Smith, J. D., Reidy, D. L., Goodman, K. A., Shia, J. & Nash, G. M. A retrospective review of 126 high-grade neuroendocrine carcinomas of the colon and rectum. Ann. Surg. Oncol. 21, 2956–2962 (2014).

PubMed  PubMed Central  Google Scholar 

Garcia-Carbonero, R. et al. ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology 103, 186–194 (2016).

CAS  PubMed  Google Scholar 

Yatabe, Y. et al. Best practices recommendations for diagnostic immunohistochemistry in lung cancer. J. Thorac. Oncol. 14, 377–407 (2019).

CAS  PubMed  Google Scholar 

Cree, I. A. et al. Counting mitoses: SI(ze) matters! Mod. Pathol. 34, 1651–1657 (2021).

PubMed  PubMed Central  Google Scholar 

Travis, W. D. et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am. J. Surg. Pathol. 22, 934–944 (1998).

CAS  PubMed  Google Scholar 

Beasley, M. B. et al. Pulmonary atypical carcinoid: predictors of survival in 106 cases. Hum. Pathol. 31, 1255–1265 (2000).

CAS  PubMed  Google Scholar 

Sorbye, H. et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann. Oncol. 24, 152–160 (2013).

CAS  PubMed  Google Scholar 

Baine, M. K. & Rekhtman, N. Multiple faces of pulmonary large cell neuroendocrine carcinoma: update with a focus on practical approach to diagnosis. Transl. Lung Cancer Res. 9, 860–878 (2020).

CAS  PubMed  PubMed Central  Google Scholar 

Febres Aldana, C. A. et al. Rb tumor suppressor in small cell lung cancer: combined genomic and immunohistochemical analysis with a description of a distinct Rb-proficient subset. Clin. Cancer Res. https://doi.org/10.1158/1078-0432.CCR-22-1115 (2022).

Article  PubMed  Google Scholar 

Dasari, A., Mehta, K., Byers, L. A., Sorbye, H. & Yao, J. C. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: a SEER database analysis of 162,983 cases. Cancer 124, 807–815 (2018).

PubMed  Google Scholar 

Ito, T. et al. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. J. Gastroenterol. 50, 58–64 (2015).

PubMed  Google Scholar 

Tsai, H.-J. et al. The epidemiology of neuroendocrine tumors in Taiwan: a nation-wide cancer registry-based study. PLoS One 8, e62487 (2013).

CAS  PubMed  PubMed Central  Google Scholar 

Leoncini, E., Carioli, G., la Vecchia, C., Boccia, S. & Rindi, G. Risk factors for neuroendocrine neoplasms: a systematic review and meta-analysis. Ann. Oncol. 27, 68–81 (2016).

CAS  PubMed  Google Scholar 

Giraldi, L. et al. Risk factors for pancreas and lung neuroendocrine neoplasms: a case-control study. Endocrine 71, 233–241 (2021).

CAS  PubMed  Google Scholar 

Varghese, A. M. et al. Small-cell lung cancers in patients who never smoked cigarettes. J. Thorac. Oncol. 9, 892–896 (2014).

CAS  PubMed  PubMed Central  Google Scholar 

Tlemsani, C. et al. Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair-targeted therapies. Sci. Transl. Med. 13, eabc7488 (2021).

CAS  PubMed  PubMed Central  Google Scholar 

Mukherjee, S. et al. Germline pathogenic variants impact clinicopathology of advanced lung cancer. Cancer Epidemiol. Biomark. Prev. 31, 1450–1459 (2022).

CAS  Google Scholar 

Quintanal-Villalonga, Á. et al. Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nat. Rev. Clin. Oncol. 17, 360–371 (2020).

PubMed  PubMed Central  Google Scholar 

Sequist, L. V. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3, 75ra26 (2011).

PubMed  PubMed Central  Google Scholar 

Rickman, D. S., Beltran, H., Demichelis, F. & Rubin, M. A. Biology and evolution of poorly differentiated neuroendocrine tumors. Nat. Med. 23, 1–10 (2017).

CAS  PubMed  Google Scholar 

Nadal, R., Schweizer, M., Kryvenko, O. N., Epstein, J. I. & Eisenberger, M. A. Small cell carcinoma of the prostate. Nat. Rev. Urol. 11, 213–219 (2014).

CAS  PubMed  PubMed Central  Google Scholar 

Quintanal-Villalonga, A. et al. Multiomic analysis of lung tumors defines pathways activated in neuroendocrine transformation. Cancer Discov. 11, 3028–3047 (2021).